Glimsentro-MV1 Tablet SR is a combination oral hypoglycemic agent formulated to improve glycemic control in patients with type 2 diabetes mellitus. It contains Glimepiride (1 mg), Metformin (500 mg), and Voglibose (0.2 mg), each contributing distinct mechanisms to regulate blood glucose levels. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to increase insulin secretion. Metformin, a biguanide, primarily reduces hepatic glucose production and enhances peripheral insulin sensitivity, thereby improving glucose uptake and utilization. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the intestine, reducing postprandial hyperglycemia. The sustained-release formulation ensures gradual drug release, promoting stable plasma concentrations and improved patient compliance. Glimsentro-MV1 is indicated for adult patients inadequately controlled on diet and exercise alone or on monotherapy. It should be used with caution in patients with renal or hepatic impairment and contraindicated in those with severe renal dysfunction, diabetic ketoacidosis, or hypersensitivity to any component. Regular monitoring of blood glucose and renal function is recommended during therapy. This combination therapy offers a comprehensive approach to managing hyperglycemia by targeting multiple pathophysiological defects in type 2 diabetes, thereby reducing the risk of long-term complications.